0000950170-24-060462.txt : 20240515 0000950170-24-060462.hdr.sgml : 20240515 20240515161137 ACCESSION NUMBER: 0000950170-24-060462 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240514 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 24950775 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 sndx-20240514.htm 8-K 8-K
0001395937false00013959372024-05-142024-05-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2024

 

 

SYNDAX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37708

32-0162505

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Building D

Floor 3

35 Gatehouse Drive

 

Waltham, Massachusetts

 

02451

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 419-1400

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

SNDX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 15, 2024, the Board of Directors (the “Board”) of Syndax Pharmaceuticals, Inc. (the “Company”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately, and appointed her as a member of the Science and Technology Committee of the Board. The Board designated Dr. Rizo as a Class III member to serve until the 2025 annual meeting of the Company’s stockholders, or until her successor has been duly elected and qualified, or until her earlier death, resignation or removal.

 

There were no arrangements or understandings between Dr. Rizo and any other persons pursuant to which she was selected as a director, and there are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission (“SEC”) between Dr. Rizo and the Company required to be disclosed herein.

 

Pursuant to the Company’s Non-Employee Director Compensation Policy (the “Policy”), Dr. Rizo will receive annual cash compensation in the amount of $45,644 for her Board service and $8,558 for her Science and Technology Committee service. All amounts will be prorated for 2024 and paid in quarterly installments. The Company will also reimburse Dr. Rizo for her travel expenses incurred in connection with her attendance at Board and Committee meetings. On May 15, 2024, the Board also granted Dr. Rizo an initial one-time option to purchase 35,000 shares of the Company’s common stock (the “Option”). Subject to Dr. Rizo’s continued service on the Board, the Option will vest as follows: 1/36 of the shares subject to the Option will vest monthly over a three-year period. In accordance with the Policy, as may be amended from time to time, Dr. Rizo will also be eligible to receive an annual equity award, subject to Dr. Rizo’s continued service on the Board.

 

In connection with her appointment to the Board, Dr. Rizo entered into the Company’s standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.21 to the Registration Statement on Form S-1 (File No. 333-208861) filed with the SEC on January 4, 2016.

 

On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately. Dr. Morrison’s resignation from the Board is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Rizo’s election fills the vacancy on the Board resulting from Dr. Morrison’s resignation.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders (the “Annual Meeting”) on May 15, 2024. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 2, 2024. Based on the votes cast in person and by proxy, each proposal passed, including the election of each director. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

 

Proposal 1: Election of directors:

 

Nominee

For

Withheld

Broker Non-Votes

Martin H. Huber, M.D.

61,876,711

736,625

3,032,770

Jennifer Jarrett

39,491,936

23,121,400

3,032,770

William Meury

54,416,889

8,196,447

3,032,770

 

Proposal 2: Advisory vote on executive compensation:

 

For

Against

Abstain

Broker Non-Votes

46,228,421

16,304,796

80,119

3,032,770

 

Proposal 3: Ratification of selection of independent registered public accounting firm:

 

For

Against

Abstain

Broker Non-Votes

65,371,337

253,270

21,499

—

Item 7.01 Regulation FD Disclosure.

A copy of the Company’s press release announcing the foregoing is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit
No.

Description

 

 

99.1

Press Release, dated May 15, 2024

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SYNDAX PHARMACEUTICALS, INC.

 

 

 

 

Date:

May 15, 2024

By:

/s/ Michael A. Metzger

 

 

 

Michael A. Metzger
Chief Executive Officer

 

 EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1

img199102934_0.jpg Exhibit 99.1

 

 

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

 

 

WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directors.

 

“On behalf of the Board, we are delighted to welcome Aleksandra to Syndax and look forward to the valuable perspectives she will bring,” said Dennis Podlesak, Chairman of Syndax’s Board of Directors. “Aleksandra is an accomplished biopharmaceutical executive and experienced hematologist who has led development and contributed to the launch of several important hematology drugs. We are confident that Aleksandra’s background and experience will enable her to make significant contributions as Syndax transitions to a fully integrated commercial stage organization with the potential to launch two novel treatments for patients and physicians in 2024.”

 

Mr. Podlesak added, “I also would like to thank Briggs for his many years of leadership and numerous contributions. He was instrumental in helping build Syndax into the world-class oncology company that it is today, and we wish him great success going forward.”

 

“Aleksandra has a deep understanding of myeloid diseases having led several programs that include clinically differentiated therapies across myeloma, lymphoma and acute myeloid leukemia,” said Michael A. Metzger, Chief Executive Officer. “Her clinical development experience and guidance will be invaluable to Syndax as we maximize the opportunity for the launch and future development of our two first- and best-in-class medicines.”

 

"I am excited to join Syndax’s Board at this transformative time for the company. Revumenib and axatilimab are approaching potential approval and I believe that both have the clinical profiles to become the new standard of care within their disease areas and expand into new indications," said Dr. Rizo. "As Syndax transitions into a commercial stage biopharmaceutical company and embarks on a new chapter, I am committed to working with the Board members and the Executive Team to support Syndax’s clinical and corporate development plans that will set the company up for long-term success."

Aleksandra Rizo, M.D., Ph.D., currently serves as President and Chief Executive Officer of Vividion where she joined in 2023 as President, Head of Research and Development.

 

 

Previously, Dr. Rizo served as Executive Vice President and Chief Medical Officer of Geron Corporation (Geron) where she provided leadership and direction for all clinical and translational efforts. Prior to joining Geron, Dr. Rizo was Strategy and Clinical Lead at Celgene Corporation where she led submission activities which resulted in successful NDA and MAA approvals for Fedratinib, and participated in strategic development activities for assets in the Myeloid Therapeutic Area, including business development evaluations. From 2008 to 2018, Dr. Rizo served in a number of oncology drug development functions with increasing responsibilities at Janssen Research and Development, LLC (Janssen), including Senior Director, Compound Development Team Leader for the myeloid portfolio, Senior Director, Global Clinical Leader for multiple assets, including imetelstat, Imbruvica for mantle cell lymphoma (MCL), and others. In these roles, she had oversight and leadership responsibilities for clinical development strategy, execution and regulatory submission activities. In addition, Dr. Rizo was a core member of Janssen’s Hematology Strategy Team where she participated and led multiple diligence projects.

Dr. Rizo earned an M.D. degree from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. Dr. Rizo obtained her Ph.D. degrees in Stem Cell Biology from the University of Groningen in the Netherlands, and the University of Tokyo in Japan.

 

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment

 

 

rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

 

 

 GRAPHIC 3 img199102934_0.jpg GRAPHIC begin 644 img199102934_0.jpg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�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end EX-101.SCH 4 sndx-20240514.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 14, 2024
Entity Registrant Name SYNDAX PHARMACEUTICALS, INC.
Entity Central Index Key 0001395937
Entity Emerging Growth Company false
Entity File Number 001-37708
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 32-0162505
Entity Address, Address Line One Building D
Entity Address, Address Line Two Floor 3
Entity Address, Address Line Three 35 Gatehouse Drive
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (781)
Local Phone Number 419-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SNDX
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports sndx-20240514.htm sndx-20240514.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sndx-20240514.htm": { "nsprefix": "sndx", "nsuri": "http://www.syndax.com/20240514", "dts": { "inline": { "local": [ "sndx-20240514.htm" ] }, "schema": { "local": [ "sndx-20240514.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_8c0b8e34-9e57-42ce-b2a6-c04b18cf2e75", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sndx-20240514.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8c0b8e34-9e57-42ce-b2a6-c04b18cf2e75", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sndx-20240514.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.syndax.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-060462-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-060462-xbrl.zip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end XML 16 sndx-20240514_htm.xml IDEA: XBRL DOCUMENT 0001395937 2024-05-14 2024-05-14 0001395937 false 8-K 2024-05-14 SYNDAX PHARMACEUTICALS, INC. DE 001-37708 32-0162505 Building D Floor 3 35 Gatehouse Drive Waltham MA 02451 (781) 419-1400 false false false false Common Stock SNDX NASDAQ false